Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cell Dev. Biol.

Sec. Cancer Cell Biology

Volume 13 - 2025 | doi: 10.3389/fcell.2025.1619359

This article is part of the Research TopicNew Advancement in Tumor Microenvironment Remodeling and Cancer Therapy, Volume IIView all 6 articles

MiR-145-5p arrests the cell cycle by modulating SMAD5/Cyclin D1 to inhibit gastric cancer progression

Provisionally accepted
Wang  LiWang Li1Jianghong  GuoJianghong Guo1Lv  CaixiaLv Caixia1,2Kong  LukeKong Luke1Cui  JingCui Jing3Zhongshuia  WangZhongshuia Wang2Guo  YuanyuanGuo Yuanyuan2Jia  RuiruiJia Ruirui4Guan  TaoGuan Tao2*Li  FengLi Feng2*Yu  BaofengYu Baofeng1*
  • 1Shanxi Medical University, Taiyuan, China
  • 2Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi Province, China
  • 3Tianjin Medical University, Tianjin, Tianjin Municipality, China
  • 4Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, China

The final, formatted version of the article will be published soon.

Purpose : This study aimed to explore the dysregulation of miR-145-5p in gastric cancer(GC) and its effects on the proliferation and cell cycle of GC cells, exploring the potential regulatory mechanism of miR-145-5p in GC. Methods:In this study, the TCGA database combined with Microarray was used to detect differentially expressed microRNA (miRNA) in GC tissues and cells. Quantitative real-time (qRT)-PCR was used to further verify the expression of miR-145-5p in GC cells and the 41 pairs of GC tissues and adjacent tissues. A retrospective analysis was conducted on the correlation between miR-145-5p and the clinicopathological characteristics of patients interfering RNA; ceRNAs, competitive endogenous RNAs; qRT-PCR, quantitative reverse transcription polymerase chain reaction.

Keywords: Mir-145-5p, Smad5, gastric cancer, Cyclin D1, Cell Cycle

Received: 28 Apr 2025; Accepted: 10 Jul 2025.

Copyright: © 2025 Li, Guo, Caixia, Luke, Jing, Wang, Yuanyuan, Ruirui, Tao, Feng and Baofeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Guan Tao, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi Province, China
Li Feng, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi Province, China
Yu Baofeng, Shanxi Medical University, Taiyuan, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.